{"id":"e2868e593321","type":"article","url":"https://hartvaat.nl/2019/03/01/ambulante-hartfrequentiereductie-na-renale-denervatie-bij-hypertensie-zonder-med/","title":"Ambulante hartfrequentiereductie na renale denervatie bij hypertensie zonder medicatie","title_en":"Ambulatory heart rate reduction after catheter-based renal denervation in hypertensive patients not receiving anti-hypertensive medications: data from SPYRAL HTN-OFF MED, a randomized, sham-controlled, proof-of-concept trial.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","bloeddrukbehandeling","chronische-nierziekte","cystatine-c","diuretica","flow-trial","ivabradine","radiance-htn","renale-denervatie","resistente-hypertensie","sacubitril-valsartan"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehy871","source_url":"https://doi.org/10.1093/eurheartj/ehy871","authors":["Michael Böhm","Felix Mahfoud","Raymond R Townsend","David E Kandzari","Stuart Pocock","Christian Ukena","Michael A Weber","Satoshi Hoshide","Manesh Patel","Crystal C Tyson","Joachim Weil","Tolga Agdirlioglu","Martin Fahy","Kazuomo Kario"],"significance":5,"published":"2019-03-01","source_date":"2019-03-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/ivabradine-bij-hartfalen/"],"congress":"","summary_en":"This SPYRAL analysis showed that renal denervation reduces ambulatory heart rate in addition to blood pressure, suggesting that sympathetic modulation extends beyond vascular tone to cardiac rate regulation.","created":"2026-07-03T10:27:48Z","updated":"2026-07-03T18:38:42Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"SPYRAL-analyse naar het effect van renale denervatie op ambulante hartfrequentie bij hypertensieve patiënten zonder antihypertensiva.","abstract_original":"AIMS: The randomized sham-controlled SPYRAL HTN-OFF MED trial demonstrated that renal denervation (RDN) using a multi-electrode catheter lowers ambulatory blood pressure (BP) in non-medicated hypertensive patients. The current report describes the effects of RDN on heart rate (HR) in this population. METHODS AND RESULTS: Patients were enrolled with an office systolic BP (SBP) of ≥150 mmHg and <180 mmHg, office diastolic BP (DBP) of ≥90 mmHg, and a mean ambulatory SBP of ≥140 mmHg and <170 mmHg. Patients were drug naïve or removed from their anti-hypertensive medications. Eighty patients were randomized 1:1 to RDN or sham procedure. This post hoc analysis examines the effect at 3 months of RDN on HR and of high baseline 24-h HR on BP and HR changes. There was a significant reduction in 24-h HR at 3 months for the RDN group (-2.5 b.p.m.) compared with sham (-0.2 b.p.m.), P = 0.003 (analysis of covariance). Mean baseline-adjusted treatment differences were significantly different between groups at 3 months for average morning HR (-4.4 b.p.m., P = 0.046) and minimum morning HR (-3.0 b.p.m., P = 0.026). RDN patients with baseline 24-h HR above the median (73.5 b.p.m.) had significant reductions in average ambulatory SBP (-10.7 mmHg difference, P = 0.001) and DBP (-7.5 mmHg, P < 0.001), whereas BP changes in RDN patients with below-median HRs were not significant. CONCLUSION: Average and minimum morning HR were significantly reduced at 3 months for RDN compared with sham patients. A baseline 24-h HR above the median predicted greater BP reductions and may allow physicians to select patients likely to respond to the procedure."}